Allergy Therapeutics PLC (DE:HHU)
FRANKFURT:HHU
HHU Stock Chart & Stats
€0.09
€0.00(0.00%)
At close: 4:00 PM EST
€0.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.07 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)14.35K
Market Cap
€625.48M
Enterprise Value€470.45M
Total Cash (Recent Filing)€10.08M
Total Debt (Recent Filing)€26.75M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume8,961
30 Day Avg. Volume14,350
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€778.57K
Bulls Say, Bears Say
Bulls Say
Immune‑modifying Business ModelAllergy Therapeutics' focus on allergen‑specific immunotherapy is a durable business model: disease‑modifying treatments target underlying causes rather than symptoms, supporting stickier demand, higher clinical barriers to competition and longer product lifecycles versus symptomatic drugs.
R&D Pipeline For Next‑gen TherapiesA stated pipeline for next‑generation allergy treatments represents a structural growth lever. Successful clinical progress or new product approvals would sustainably expand addressable markets, improve product mix, and create long‑term differentiation versus incumbents reliant on older therapies.
Established Operational ScaleA headcount of ~612 indicates an established operational footprint capable of supporting R&D, regulatory, and commercial activities. That scale underpins capacity to run clinical programs and commercial rollout without starting from scratch, aiding durability of development and go‑to‑market plans.
Bears Say
Stressed Balance SheetNegative equity and a high leverage ratio are structural constraints: they limit financial flexibility, raise refinancing and covenant risk, and increase likelihood of dilution or asset sales to fund operations, impairing the company's ability to invest consistently over months.
Negative Operating And Free Cash FlowPersistently negative operating and free cash flows indicate the business cannot self‑fund R&D or commercial expansion. Over the medium term this creates dependence on external capital, heightens liquidity risk, and may force strategic cutbacks or unfavorable financing that weaken long‑term prospects.
Declining Revenue And Weak MarginsA trend of falling revenue combined with deep negative margins undermines sustainable profitability. Structural revenue erosion and loss generation restrict reinvestment, make scaling difficult, and raise questions about commercial effectiveness and pricing power over the coming months.
Allergy Therapeutics News
HHU FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest stock price was €0.07 and its highest was €0.16 in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is €625.48M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 109 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in DE:HHU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.48%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---